Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allogeneic DCs and Autologous RCC Tumor Derived Cells · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Allogeneic DCs and Autologous RCC Tumor Derived Cells | DRUG | - |
Inclusion Criteria: * The patient must be greater than or equal to 18 years of age. * The patient must be diagnosed with AJCC Stage IV (primary or relapsed) Renal Cell Carcinoma. * The patient must have a Screening Eastern Cooperative Oncology Group (ECOG) Clinical Performance Status of 0-1. * The ...
Allogeneic DCs and Autologous RCC Tumor Derived Cells is an investigational therapy being studied for renal cell carcinoma, a type of kidney cancer. It was evaluated specifically in patients with advanced kidney cancer. The approach combines dendritic cells with tumor cells in a vaccine formulation intended to stimulate an immune response against the cancer.
Sanofi is the developer of Allogeneic DCs and Autologous RCC Tumor Derived Cells. Sanofi trades on the New York Stock Exchange under the ticker symbol SNY. The company sponsored the clinical research evaluating this dendritic cell and tumor cell vaccine approach in renal cell carcinoma.
Allogeneic DCs and Autologous RCC Tumor Derived Cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 1 trial evaluating this vaccine in advanced kidney cancer has been completed.
Allogeneic DCs and Autologous RCC Tumor Derived Cells was evaluated in one completed Phase 1 trial, NCT00050323, titled Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer. The trial enrolled 30 participants in the United States and included adults 18 years and older of all sexes.
The Phase 1 trial NCT00050323 was an uncontrolled, non-randomized, open-label study. It enrolled 30 participants with advanced renal cell carcinoma across sites in the United States. Participants were 18 years of age or older, and the study did not include healthy volunteers. The trial has been completed.